Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
Open accessThe DOI matches its Crossref record; 94 of the 96 references it cites were found in a registry or an index.
Abstract
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation carfilzomib is irreversible and more specifically inhibits chymotrypsin-like activity than bortezomib, the reversible first-generation inhibitor, which also inhibits lysosomal and calcium-activated cellular proteases (54, 83).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“bortezomib use in humans was associated with peripheral neuropathy, thrombocytopenia, and neutropenia (70).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [70]
In the citing paper
“Proteasome inhibitors (PIs) are licensed for multiple myeloma.”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [54]
In the citing paper
“Although no toxicity was found in the animal models, peripheral neuropathy and myelosuppression are adverse effects observed in humans (54).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Phase 2 studies demonstrating the effectiveness of this agent in relapsed/refractory MM were reported 11 years ago [30].”
BackgroundImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Hideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,673
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
The proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. H. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,143
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Siegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 657
Richardson, P. G., Briemberg, H., Jagannath, S., Wen, P. Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D. S., Irwin, D., Schuster, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7779 · Cited by 649
Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 593
Proteasome inhibitors in multiple myeloma: 10 years later
Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L. (2012) · Blood · doi:10.1182/blood-2012-04-403733 · Cited by 490
Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104950 · Cited by 454
LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D. S., Goloubeva, O. G., Pien, C. S., Adams, J., et al. (2002) · PubMed · Cited by 450
Kumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446
Argyriou, A. A., Iconomou, G., & Kalofonos, H. P. (2008) · Blood · doi:10.1182/blood-2008-04-149385 · Cited by 432
Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422683 · Cited by 423
Ma, M. H., Yang, H. H., Parker, K., Manyak, S. J., Friedman, J. M., Altamirano, C. V., Wu, Z.-Q., Borad, M. J., Frantzen, M., Roussos, E., et al. (2003) · PubMed · Cited by 414
Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition
Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2258 · Cited by 410
Arastu-Kapur, S., Anderl, J. L., Kraus, M., Parlati, F., Shenk, K. D., Lee, S. J., Muchamuel, T., Bennett, M. K., Driessen, C., Ball, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1950 · Cited by 408
Palumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H., Anderson, K. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 392
Reeder, C. B., Reece, D. E., Kukreti, V, Chen, C., Trudel, S., Hentz, J., Noble, B., Pirooz, N. A., Spong, J. E., Piza, J. G., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 372
Siegel, D., Martin, T., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., Badros, A. Z., Jagannath, S., McCulloch, L., Rajangam, K., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.089334 · Cited by 347
Lonial, S., Waller, E. K., Richardson, P. G., Jagannath, S., Orlowski, R. Z., Giver, C. R., Jaye, D. L., Francis, D., Giusti, S., Torre, C., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1173 · Cited by 340
Richardson, P. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M. S., Khan, M., Paley, C. S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-481325 · Cited by 290
Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)
Han, Y., & Smith, M. T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00156 · Cited by 273
Zhou, H.-J., Aujay, M. A., Bennett, M. K., Dajee, M., Demo, S. D., Fang, Y., Ho, M. N., Jiang, J., Kirk, C. J., Laidig, G. J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801329v · Cited by 272
Hideshima, T., Richardson, P. G., & Anderson, K. C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0433 · Cited by 265
Vij, R., Wang, M., Kaufman, J. L., Lonial, S., Jakubowiak, A. J., Stewart, A. K., Kukreti, V., Jagannath, S., McDonagh, K. T., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-03-414359 · Cited by 255
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., Terpos, E., Munshi, N., Palumbo, A., Rajkumar, S. V., et al. (2012) · Leukemia · doi:10.1038/leu.2011.346 · Cited by 253
Nawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Andtbacka, R. H. I., Dunner, K., Pal, A., Bornmann, W. G., Chiao, P. J., Huang, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2961 · Cited by 240
Ocio, E. M., Richardson, P. G., Rajkumar, S. V., Palumbo, A., Mateos, M. V., Orlowski, R., Kumar, S., Usmani, S., Roodman, D., Niesvizky, R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 233
Dimopoulos, M., Siegel, D. S., Lonial, S., Qi, J., Hajek, R., Facon, T., Rosinol, L., Williams, C., Blacklock, H., Goldschmidt, H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70398-x · Cited by 232
Broyl, A., Corthals, S. L., Jongen, J. L., van der Holt, B., Kuiper, R., de Knegt, Y., van Duin, M., el Jarari, L., Bertsch, U., Lokhorst, H. M., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70206-0 · Cited by 219
Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., Patriarca, F., Levi, A., Benevolo, G., Vincelli, I. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0023 · Cited by 211
Kuhn, D. J., Hunsucker, S. A., Chen, Q., Voorhees, P. M., Orlowski, M., & Orlowski, R. Z. (2009) · Blood · doi:10.1182/blood-2008-07-171637 · Cited by 207
Kortuem, K. M., & Stewart, A. K. (2013) · Blood · doi:10.1182/blood-2012-10-459883 · Cited by 200
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
Kubiczkova, L., Pour, L., Sedlarikova, L., Hajek, R., & Sevcikova, S. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12279 · Cited by 187
Vij, R., Siegel, D. S., Jagannath, S., Jakubowiak, A. J., Stewart, A. K., McDonagh, K., Bahlis, N., Belch, A., Kunkel, L. A., Wear, S., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09232.x · Cited by 177
Vincenz, L., Jäger, R., O'Dwyer, M., & Samali, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0782 · Cited by 175
Huber, E. M., & Groll, M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201616 · Cited by 174
The resistance mechanisms of proteasome inhibitor bortezomib
Lü, S., & Wang, J. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-13 · Cited by 164
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
Badros, A. Z., Vij, R., Martin, T., Zonder, J. A., Kunkel, L., Wang, Z., Lee, S., Wong, A. F., & Niesvizky, R. (2013) · Leukemia · doi:10.1038/leu.2013.29 · Cited by 150
Dimopoulos, M. A., Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Shpilberg, O., Kropff, M., Spicka, I., Palumbo, A., Wu, K. L., et al. (2011) · European Journal of Haematology · doi:10.1111/j.1600-0609.2010.01533.x · Cited by 142
San-Miguel, J. F., Richardson, P. G., Günther, A., Sezer, O., Siegel, D., Bladé, J., LeBlanc, R., Sutherland, H., Sopala, M., Mishra, K. K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.7068 · Cited by 139
Wang, M., Martin, T., Bensinger, W., Alsina, M., Siegel, D. S., Kavalerchik, E., Huang, M., Orlowski, R. Z., & Niesvizky, R. (2013) · Blood · doi:10.1182/blood-2013-07-511170 · Cited by 129
Arnulf, B., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., van de Velde, H., Feng, H., Cakana, A., Deraedt, W., & Moreau, P. (2012) · Haematologica · doi:10.3324/haematol.2012.067793 · Cited by 127
Nawrocki, S. T., Carew, J. S., Maclean, K. H., Courage, J. F., Huang, P., Houghton, J. A., Cleveland, J. L., Giles, F. J., & McConkey, D. J. (2008) · Blood · doi:10.1182/blood-2007-12-130823 · Cited by 121
Lü, S., Yang, J., Song, X., Gong, S., Zhou, H., Guo, L., Song, N., Bao, X., Chen, P., & Wang, J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138131 · Cited by 109
Vickrey, E., Allen, S., Mehta, J., & Singhal, S. (2008) · Cancer · doi:10.1002/cncr.24006 · Cited by 108
Ludwig, H., Kasparu, H., Leitgeb, C., Rauch, E., Linkesch, W., Zojer, N., Greil, R., Seebacher, A., Pour, L., Weißmann, A., et al. (2014) · Blood · doi:10.1182/blood-2013-08-521468 · Cited by 100
Inhibitors of the Immunoproteasome: Current Status and Future Directions
Miller, Z., Ao, L., Bo Kim, K., & Lee, W. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319220018 · Cited by 99
Lonial, S., Richardson, P. G., San Miguel, J., Sonneveld, P., Schuster, M. W., Bladé, J., Cavenagh, J., Rajkumar, S. V., Jakubowiak, A. J., Esseltine, D., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07321.x · Cited by 94
A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
Sborov, D. W., Nuovo, G. J., Stiff, A., Mace, T., Lesinski, G. B., Benson, D. M., Efebera, Y. A., Rosko, A. E., Pichiorri, F., Grever, M. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1404 · Cited by 91
Bortezomib Combination Therapy in Multiple Myeloma
Kapoor, P., Ramakrishnan, V. G., & Rajkumar, S. V. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.010 · Cited by 85
Kelly, K. R., Espitia, C. M., Mahalingam, D., Oyajobi, B. O., Coffey, M. C., Giles, F. J., Carew, J. S., & Nawrocki, S. T. (2011) · Oncogene · doi:10.1038/onc.2011.478 · Cited by 83
Self-citationThe Immunoproteasome as a Target in Hematologic Malignancies
Kuhn, D. J., & Orlowski, R. Z. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.003 · Cited by 82
Jakubowiak, A. J., Siegel, D. S. D., Martin, T., Wang, M., Vij, R., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N. J., Alsina, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.152 · Cited by 79
Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Stessman, H. A. F., Baughn, L. B., Sarver, A., Xia, T., Deshpande, R., Mansoor, A., Walsh, S. A., Sunderland, J. J., Dolloff, N. G., Linden, M. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1151 · Cited by 79
The aggresome pathway as a target for therapy in hematologic malignancies
Simms-Waldrip, T. R., Rodríguez-González, A., Lin, T. L., Ikeda, A. K., Fu, C. H., & Sakamoto, K. M. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.03.012 · Cited by 78
New orally active proteasome inhibitors in multiple myeloma
Allegra, A., Alonci, A., Gerace, D., Russo, S., Innao, V., Calabrò, L., & Musolino, C. (2014) · Leukemia Research · doi:10.1016/j.leukres.2013.10.018 · Cited by 74
Li, Y., Kufe, T., Avigan, D., & Kufe, D. W. (2014) · Blood · doi:10.1182/blood-2013-11-539395 · Cited by 67
Current strategies for treatment of relapsed/refractory multiple myeloma
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A., Lonial, S., & Richardson, P. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 67
Neurotoxicity induced by antineoplastic proteasome inhibitors
Alé, A., Bruna, J., Navarro, X., & Udina, E. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.02.001 · Cited by 62
Richardson, P. G. G., Mitsiades, C. S., Laubach, J. P., Hájek, R., Špıčka, I., Dimopoulos, M. A., Moreau, P., Siegel, D. S. D., Jagannath, S., & Anderson, K. C. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.03.006 · Cited by 58
Proteasome inhibitors in the treatment of multiple myeloma
McBride, A., & Ryan, P. Y. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.9 · Cited by 58
Jung, T., & Grune, T. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-397863-9.00001-8 · Cited by 53
Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview
Jakubowiak, A. J. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.005 · Cited by 49
Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With Bortezomib
Heider, U., Rademacher, J., Kaiser, M., Kleeberg, L., von Metzler, I., & Sezer, O. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.019 · Cited by 48
Fuchs, O. (2013) · Cardiovascular & Hematological Disorders-Drug Targets · doi:10.2174/1871529x11313010003 · Cited by 47
Hrusovsky, I., Emmerich, B., von Rohr, A., Voegeli, J., Taverna, C., Olie, R. A., Pliskat, H., Frohn, C., & Hess, G. (2010) · Oncology · doi:10.1159/000322866 · Cited by 44
Panobinostat for the treatment of multiple myeloma
Neri, P. E., Bahlis, N. J., & Lonial, S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.668883 · Cited by 39
Cvek, B. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-397863-9.00005-5 · Cited by 39
Manasanch, E. E., Korde, N., Zingone, A., Tageja, N., de Larrea, C. F., Bhutani, M., Wu, S. P., Roschewski, M. J., & Landgren, O. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.828351 · Cited by 36
Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma
Orlowski, R. Z. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.014 · Cited by 33
Bortezomib in Multiple Myeloma: A Practice Guideline
Kouroukis, C. T., Baldassarre, F. G., Haynes, A. E., Imrie, K., Reece, D. E., & Cheung, M. C. (2013) · Clinical Oncology · doi:10.1016/j.clon.2013.11.022 · Cited by 25
Broyl, A., Jongen, J. L. M., & Sonneveld, P. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.001 · Cited by 24
Low‐dose acyclovir prophylaxis for bortezomib‐induced herpes zoster in multiple myeloma patients
Minařík, J., Pika, T., Bačovský, J., Langová, K., & Ščudla, V. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09233.x · Cited by 23
Agyin, J. K., Santhamma, B., & Roy, S. S. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.09.043 · Cited by 23
Bortezomib for the treatment of multiple myeloma
Grosicki, S., Barchnicka, A., Jurczyszyn, A. J., & Grosicka, A. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.899144 · Cited by 20
Hoy, S. M. (2013) · Drugs · doi:10.1007/s40265-013-0006-6 · Cited by 18
Drug Combinations with Proteasome Inhibitors in Antitumor Therapy
Gatti, L., Zuco, V., Zaffaroni, N., & Perego, P. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319220015 · Cited by 18
Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
Thirukkumaran, C. M., & Morris, D. G. (2011) · Bone Marrow Research · doi:10.1155/2011/632948 · Cited by 15
Wang, L., Xu, Y., & Zhang, X. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.838232 · Cited by 14
193Normal hematopoietic stem cell function in mice following treatment with bortezomib
Pitzgerald, M., Fraser, C., Webb, I. J., Schenkein, D. P., Esseltine, D. L., & Weich, N. S. (2003) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(03)80186-6 · Cited by 14
Romano, A., Chiarenza, A., Conticello, C., Cavalli, M. M., Vetro, C., Raimondo, C. D., Cunsolo, R., Palumbo, G. A., & Raimondo, F. D. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12325 · Cited by 13
Uy, G. L., Peles, S., Fisher, N. M., Tomasson, M. H., DiPersio, J. F., & Vij, R. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.11.355 · Cited by 13
Savona, M. R., Berdeja, J. G., Lee, S. H., Wong, H. L., Lee, J. R., Gillenwater, H. H., & Siegel, D. S. D. (2012) · Blood · doi:10.1182/blood.v120.21.203.203 · Cited by 9
Bortezomib resistance and MUC1 in myeloma
Grant, S. (2014) · Blood · doi:10.1182/blood-2014-03-563882 · Cited by 6
Proteasome inhibitor patents (2010 – present)
Metcalf, R. S., Scott, L. M., Daniel, K. G., & Dou, Q. P. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.877444 · Cited by 5
Research works printed but not linked: 1
- Kaufman, J.L., and Siegal, D. (2013, January 21). Haematologica. Clinical Profile of Once-Daily, Modified-Release Oprozomib Tablets in Patients with Hematologic Malignancies: Results of a Phase 1b/2 Trial. Proceedings of Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology Association, South San Francisco, CA, USA.
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Spencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M.-D., Bosi, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194118 · Cited by 263
Discovery and characterization of highly potent and selective allosteric USP7 inhibitors
Gavory, G., O'Dowd, C. R., Helm, M. D., Flasz, J., Arkoudis, E., Dossang, A., Hughes, C., Cassidy, E., McClelland, K., Odrzywol, E., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2528 · Cited by 224
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Serrano-del Valle, A., Anel, A., Naval, J., & Marzo, I. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00050 · Cited by 198
Multiple myeloma in the marrow: pathogenesis and treatments
Fairfield, H., Falank, C., Avery, L., & Reagan, M. R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13038 · Cited by 183
Metadata
- Authors
- Merin, N., & Kelly, K.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Kelly, Kevin
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2014-12-24
- Volume
- 8
- Issue
- 1
- Pages
- 1-20
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC4381198
- OpenAlex
- W1994895013
- Cited by
- 90
- References
- 96
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 6 · 2021: 12 · 2020: 5 · 2019: 7 · 2018: 12 · 2017: 6 · 2016: 13 · 2015: 5
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- California Institute for Regenerative Medicine
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- multiple myeloma, proteasome inhibitors, bortezomib, carfilzomib, adverse drug reactions, combination therapy, plasma cell neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.